Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Nanobiotix S.A. - ADSs
(NQ:
NBTX
)
21.16
+0.16 (+0.76%)
Streaming Delayed Price
Updated: 12:32 PM EST, Feb 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nanobiotix S.A. - ADSs
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Earnings Scheduled For April 2, 2025
↗
April 02, 2025
Via
Benzinga
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
March 31, 2025
Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
March 27, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
March 20, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden
↗
March 18, 2025
Nanobiotix amended its $2.7 billion licensing deal with Johnson & Johnson, reducing costs while retaining key milestone payments. The update extends its cash runway to mid-2026.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
March 17, 2025
Via
Benzinga
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
March 17, 2025
Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
March 13, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
February 12, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025
January 29, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
January 21, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
January 09, 2025
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
December 17, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
December 11, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Why C3.ai Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
↗
December 10, 2024
Via
Benzinga
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
December 09, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
November 13, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
November 12, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Participate in Multiple Investor Conferences in November
October 31, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
October 11, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
September 18, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
September 04, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
August 08, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
July 09, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
June 12, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
June 11, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
June 02, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
May 28, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
May 23, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
